[PDF][PDF] Reduction of peripheral blood T cells producing IFN-γ and IL-17 after therapy with abatacept for rheumatoid arthritis
M Scarsi, C Zanotti, M Chiarini, L Imberti… - Clin Exp …, 2014 - clinexprheumatol.org
M Scarsi, C Zanotti, M Chiarini, L Imberti, S Piantoni, M Frassi, A Tincani, P Airò
Clin Exp Rheumatol, 2014•clinexprheumatol.orgObjective Abatacept (ABA), a molecule used in the treatment of rheumatoid arthritis (RA),
competes with the engagement of CD28, a T-cell receptor for co-stimulatory signals. CD28-
mediated signalling regulates several T-cell functions, including inflammatory cytokine
production and regulatory T cells (Treg) differentiation. Therefore, our objective was to
evaluate the effects of ABA on peripheral blood T-lymphocyte cytokine production and on
the number of circulating Treg.
competes with the engagement of CD28, a T-cell receptor for co-stimulatory signals. CD28-
mediated signalling regulates several T-cell functions, including inflammatory cytokine
production and regulatory T cells (Treg) differentiation. Therefore, our objective was to
evaluate the effects of ABA on peripheral blood T-lymphocyte cytokine production and on
the number of circulating Treg.
Objective
Abatacept (ABA), a molecule used in the treatment of rheumatoid arthritis (RA), competes with the engagement of CD28, a T-cell receptor for co-stimulatory signals. CD28-mediated signalling regulates several T-cell functions, including inflammatory cytokine production and regulatory T cells (Treg) differentiation. Therefore, our objective was to evaluate the effects of ABA on peripheral blood T-lymphocyte cytokine production and on the number of circulating Treg.
clinexprheumatol.org